UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the ...

We had another strong quarter with 3.5 billion people using at least one of our apps every day. Building personal superintelligence for everyone, delivering the app experiences and computing devices ...